The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine

详细信息    查看全文

• 作者：Marylin Madamet ; Sébastien Briolant ; Rémy Amalvict ; Nicolas Benoit…
• 关键词：Malaria ; Plasmodium falciparum ; Antimalarial ; Resistance ; In vitro ; Molecular marker ; pfcrt
• 刊名：Parasites & Vectors
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：9
• 期：1
• 全文大小：506 KB
• 参考文献：1.Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Review of pyronaridineanti-malarial properties and product characteristics. Malar J. 2012;11:270.PubMedCentral CrossRef PubMed
  2.Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457–67.CrossRef PubMed
  3.Kayentao K, Doumbo OK, Pénali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.PubMedCentral CrossRef PubMed
  4.Rueangweerayu R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al. Pyronaridine–artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012;366:1298–309.CrossRef
  5.Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011;6:14501.CrossRef
  6.Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.PubMedCentral CrossRef PubMed
  7.Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2015;371:411–23.CrossRef
  8.Leang R, Taylor WRJ, MeyBouth D, Song L, Tarning J, Chuor Char M, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: Dihydroartemisinin-piperaquine open-label multicentre clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.PubMedCentral CrossRef PubMed
  9.Spring M, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including Kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683–93.CrossRef PubMed
  10.Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, et al. Multinormalin vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J. 2015;14:49.PubMedCentral CrossRef PubMed
  11.Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, et al. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J. 2012;11:45.PubMedCentral CrossRef PubMed
  12.Price RN, Marfurt J, Chalfein F, Kenagalem E, Piera KA, Tjitra E, et al. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparumand Plasmodium vivax. Antimicrob Agents Chemother. 2010;54:5146–50.PubMedCentral CrossRef PubMed
  13.Briolant S, Henry M, Oeuvray C, Amalvict R, Baret E, Didillon E, et al. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother. 2010;54:3537–44.PubMedCentral CrossRef PubMed
  14.Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, et al. In vitropiperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J. 2013;12:431.PubMedCentral CrossRef PubMed
  15.Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, et al. Absence of association between pyronaridinein vitro responses and polymorphisms involved in quinoline resistance in Plasmodium falciparum. Malar J. 2010;9:339.PubMedCentral CrossRef PubMed
  16.Okombo J, Kiara SM, Mwai L, Pole L, Ohuma E, Ochola LI, et al. Baseline In vitro activities of the antimalarialspyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya. Antimicrob Agents Chemother. 2012;56:1105–7.PubMedCentral CrossRef PubMed
  17.Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009;55:5069–73.CrossRef
  18.Hao M, Jia D, Li Q, He Y, Yuan L, Xu S, et al. In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to Piperaquine and association with polymorphisms in candidate genes. Antimicrob Agents Chemother. 2013;57:1723–9.PubMedCentral CrossRef PubMed
  19.Okombo J, Abdi AI, Kiara SM, Mwai L, Pole L, Sutherland CJ, et al. Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses. Antimicrob Agents Chemother. 2013;57:6196–204.PubMedCentral CrossRef PubMed
  20.Henrich PP, O'Brien C, Sáenz FE, Cremers S, Kyle DE, Fidock DA. Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model. Antimicrob Agents Chemother. 2014;58:183–95.PubMedCentral CrossRef PubMed
  21.Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2015. doi:10.​1016/​S1473-3099(15)00318-7 .PubMed
  
• 作者单位：Marylin Madamet (1) (2) (3)
  Sébastien Briolant (2) (4) (5) (6)
  Rémy Amalvict (1) (2) (3)
  Nicolas Benoit (1) (2) (3)
  Housem Bouchiba (2) (4)
  Julien Cren (2) (4)
  Bruno Pradines (2) (3) (4)
  the French National Centre for Imported Malaria Study Group
  
  1. Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Hôpital d’Instruction des Armées Laveran, Marseille, France
  2. Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Aix Marseille Université, UM 63, CNRS 7278, IRD 198, Inserm 1095, Marseille, France
  3. Centre National de Référence du Paludisme, Marseille, France
  4. Unité de Parasitologie et d’Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
  5. Direction Interarmées du Service de Santé, Cayenne, Guyane, France
  6. Laboratoire de Parasitologie, Institut Pasteur de la Guyane, Cayenne, Guyane, France
  
• 刊物主题：Parasitology; Infectious Diseases; Tropical Medicine; Entomology;
• 出版者：BioMed Central
• ISSN：1756-3305

文摘

Background The pyronaridine-artesunate combination is one of the most recent oral artemisinin-based therapeutic combinations (ACTs) recommended for the treatment of uncomplicated P. falciparum malaria. The emergence of P. falciparum resistance to artemisinin has recently developed in Southeast Asia. Little data are available on the association between pyronaridine susceptibility and polymorphisms in genes involved in antimalarial drug resistance. The objective of the present study was to investigate the association between ex vivo responses to pyronaridine and the K76T mutation in the pfcrt gene in P. falciparum isolates.